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Introduction
============

The results of primary outcomes in randomized controlled trials are often influenced by factors other than the treatment. Examples include recruiting site characteristics in multicenter trials such as the type and number of sites[@ref1] as well as various participants' characteristics such as age, sex, and body weight.[@ref2] These variables are often used as stratification factors during randomization.[@ref3] Some participants' characteristics are asymmetrically distributed between the study arms despite randomization; and the likelihood of imbalance is higher in trials with a small sample and when randomization procedures are not followed properly. At present there is no consistent practice as to how to handle the imbalance between the study groups in analysis.[@ref2] [@ref4] [@ref5] Some studies adjust the outcome model for baseline differences among study groups. Other studies consider baseline differences to be chance findings and therefore not to be adjusted for, and many methodologists argue against even checking for them.[@ref6]

Different choices for adjustment may lead to different estimates of the treatment effect and levels of statistical significance. The variability in treatment effects estimates due to multiple analytical choices has been described as "vibration of effects": each analysis with or without various adjustments may give somewhat different results.[@ref7] Making adjustments should have little impact on the conclusions, when the effect size is large and its clinical importance is not contestable or even when the effect size is modest but the amount of evidence is large. Most randomized controlled trials are, however, not large[@ref8] and when the presence of an effect is tenuous (for example, when the results hover around the "attractive" P value of 0.05),[@ref9] decisions regarding adjustment may influence the interpretation of the study outcome. Vibration of effects may lead to biased results, if multiple possible adjustment schemes are performed retrospectively and the most favorable result is then selectively reported or highlighted.

Several measures can be taken to reduce the disparate practices in the analysis of data from randomized controlled trials to increase transparency and overall reproducibility of clinical research. The ideal practice would be that the trial investigators make the protocol, dataset, and analytical code publicly available. Alternately, investigators could provide as much raw data as possible using detailed tables and figures either in the trial publications or in the registry. Minimally, investigators should follow the standardized reporting guidelines that are already in place for randomized controlled trials. For example, the CONSORT statement and ICH E9 (statistical principles for clinical trials) provide explicit instructions on statistical analyses in randomized controlled trials, including model adjustment for baseline differences and stratified randomization factors.[@ref10] [@ref11]

In this analysis we evaluated a sample (n=200) of randomized controlled trials published in high impact journals in 2009. We gathered all relevant information about planned statistical analysis of the primary outcome from trial registries, design papers, and protocols provided by the authors. We assessed differences in the statistical plan for model adjustment between the trial protocol and the trial publication for those trials with available protocols. For the sample of all 200 trials we also assessed the congruency of model adjustment for primary outcomes between the trial methods and results section. We examined which factors were used for adjustment and evaluated the extent to which adjusted and unadjusted treatment effects differ in level of nominal statistical significance.

Methods
=======

We searched PubMed to locate the relevant trials. We categorized the search term according to study type (randomized controlled trial) and journal (*BMJ*, *American Journal of Psychiatry*, *American Journal of Respiratory Critical Care Medicine*, *Annals of Internal Medicine*, *Annals of Neurology*, *Archives of General Psychiatry*, *Archives of Internal Medicine*, *Blood*, *Brain*, *Circulation*, *European Heart Journal*, *Gastroenterology*, *Gut*, *Hepatology*, *Journal of Allergy and Clinical Immunity*, *Journal of the American College of Cardiology*, *Journal of Clinical Oncology*, *Journal of the National Cancer Institute*, *JAMA*, *Lancet*, *Lancet Infectious Diseases*, *Lancet Neurology*, *Lancet Oncology*, *New England Journal of Medicine*, and *PLoS Medicine*). The 25 biomedical journals were selected as having the highest impact factor (per *Journal Citation Reports* 2009 edition) among journals that may publish clinical trials. The "AND" Boolean operator was used to combine search terms between the categories and the "OR" was used within the category for journals. We limited the search to studies that involved human participants and were published in 2009.

We screened the abstract using the inclusion criteria of randomized controlled trial, published in print in 2009, and main trial paper with primary outcome. We randomly selected 200 from the eligible articles.

Protocol assessment of included randomized controlled trials
------------------------------------------------------------

*Registration entries*---We searched the trial papers to determine whether the study was registered. If the registry number was available, we checked the appropriate trial registry online and extracted information on the use of model adjustment for the primary outcome from general registration information, study results, or full study protocols that might be available in the registry for each trial.

*Original protocol through personal communication*---We identified the corresponding author and his or her contact information for each trial. We emailed each author with a brief description of our study and requested the full original study protocol. We waited two weeks for a response and sent a reminder email to those who had not responded.

*Design paper search*---We searched the registry as well as the reference list of the trial publication to see whether a design paper had been published. We obtained full text of the design papers through PubMed and extracted information on the use of model adjustment for the primary outcome. Additionally, some authors sent us a design paper during our email communication with them.

Data extraction from publications of randomized controlled trials
-----------------------------------------------------------------

From each trial we extracted the following information: study arms, primary outcomes, sample size, number of sites, whether randomization was stratified, and whether arms were compared for baseline characteristics. We considered baseline differences to be statistically significant when P values were given or the text included the word "significant" for the comparison.

We recorded whether any adjustments were planned for the primary outcome in the Methods section and whether these analyses were respectively reported in the Results section. We defined a model as adjusted if explicit statements regarding adjustment were made, covariates were listed, or a statistical test that by definition is multivariate (for example, multiple logistic regression, multivariate analysis of variance) was reported. Whenever adjustments were made, we recorded whether they used variables that had been used in the stratification of the randomization or the baseline characteristics, and which variables were involved. To avoid double counting, if a variable had been used for the stratified randomization then it was not counted as a baseline characteristic; otherwise, baseline variables include all those mentioned in the text or table as measured at baseline. Finally, we recorded the unadjusted estimate and 95% confidence interval of the treatment effect of the primary outcome and any adjusted estimates for the same treatment comparison. For trials with multiple primary outcomes, we selected the outcome on which the sample size calculation was based.

Two researchers (NS and JS) independently extracted data. The pilot phase involved data extraction from 30 articles; the model adjustment data were in full agreement in two thirds of the cases. At the end of the pilot phase, the two researchers met with the senior investigator (JPAI) to resolve the discrepancies, to finalize the definition, and to streamline the protocol. At the end of the full data extraction phase, the two researchers discussed discrepancies in model adjustment data and were able to reach a consensus in all but four cases, which were arbitrated by the senior investigator.

Statistical analysis
--------------------

We compared the model adjustment plan provided in the main trial publication with the corresponding information extracted from the registry, protocol, or design paper, to see if these did or did not agree. We also calculated the proportion of trials that reported statistically significant effects in each of the categories of agreement. For trials where the protocol and the publication had different analysis plans, we also recorded what the results were for analyses that had not been specified in the protocol but had been added in the publication.

From the sample of all 200 trials we generated frequency tables for categorical variables and measures of central tendency (that is, mean, median) and range for continuous variables pertaining to general trial characteristics and adjustment procedures. We identified the most common variables adjusted for and calculated the percentage of trials that reported them.

To achieve consistency across trials, we presented effect sizes in such a manner that relative risk metrics \<1.00 and risk difference and mean difference metrics \<0 indicate that the experimental intervention is better than the control intervention. Whenever both adjusted and unadjusted treatment effects were reported, we examined the concordance of the level of nominal statistical significance, based on 95% confidence intervals being entirely on one side of the null, P values \<0.05, or a statement in the text. Whenever nominal significance was reached with only one analysis but not the other, we also noted whether the authors of the trial focused on the significant or non-significant result primarily in interpreting their findings.

Statistical analyses were conducted in SAS version 9.2 (Cary, NC). All P values are two tailed.

Results
=======

The search resulted in 1123 articles. We excluded a total of 439 articles; 163 papers were not randomized controlled trials, 94 papers were published in print in 2010 (published electronically in 2009, but appeared in print in 2010), and 182 were secondary studies using the population of the original randomized controlled trial (that is, extended follow-up or subset analyses). Then, of the 200 randomly selected articles, two papers each reported the results from two separate trials and these were considered separately; conversely, we excluded three trials that had not analyzed primary outcomes between the study arms. Analysis included 199 trials (see supplementary file).

Comparison between trial protocols and main paper
-------------------------------------------------

Most of the 199 trials (81%, n=162) were registered; the most common registries included clinicaltrials.gov (n=109), International Standard Randomized Controlled Trial Number (ISRCTN) (n=41), and Australia New Zealand Clinical Trial Registry (ANZCTR) (n=6). General information on registration was available for the majority of the trials; study results were available for only 12% (20/162) of the trials. Statistical procedures such as model adjustment were found only in 6% (9/162) of the trials. Of the trials, 15% (30/199) had published design papers and 70% (21/30) of them provided information on model adjustment. We evaluated 54 original protocols, sent to us by the authors, and found that 74% (40/54) included an analysis section with a model adjustment plan. In total, 31% (61/199) of the trials had available information on adjustment from the registry, design paper, or protocol (figure[](#fig1){ref-type="fig"}).

![Flow diagram for 199 evaluated trials: availability of information on model adjustment for primary outcomes from trial registry, design paper, or full protocol provided by trial authors](saqn005580.f1_default){#fig1}

We compared the analysis plans from the main paper with the plan reported in the registry, protocol, or design paper for 60 trials (the plan was unclear for one published trial). The adjustment plan matched in 53% (32/60) of the trials; of them, 62% (20/32) reported a significant effect. Among the trials where the adjustment plan did not match, 53% (15/28) reported a significant effect. Of the 28 identified trials where the plan in the protocol did not match what was reported eventually in the publication, 75% (n=21) reported analyses that had not been specified in the protocol and, of them, 62% (13/21) were statistically significant; whereas 25% (n=7) did not report analyses that had been specified in the protocol and 29% (2/7) of the reported analyses were statistically significant.

Characteristics of selected trials
----------------------------------

Three quarters (77%) of the 199 reviewed trials had only two study arms, and a similar percentage (76%) of the trials assessed a single primary outcome. Most trials (69%) enrolled participants from multiple study sites (median 20, range 2-862 sites). More than half (54%) used stratified randomization. Almost all trials (96%) presented baseline characteristics per arm. About half (46%) tested statistically for differences in baseline characteristics, and 22% claimed statistically significant differences in baseline characteristics (table 1[](#tbl1){ref-type="table"}).

###### 

 Description of trials in analysis. Values are numbers (percentages) unless stated otherwise.

  Variables                                     Trials (n=199)
  --------------------------------------------- ------------------
  No of study arms:                             
   2                                            154 (77)
   3                                            28 (14)
   ≥4                                           17 (9)
  No of primary outcomes:                       
   1                                            152 (76)
   2                                            27 (14)
   ≥3                                           20 (10)
  Setting:                                      
   Single site                                  58 (29)
   Multisite                                    137 (69)
   Missing information                          4 (2)
  Randomization:                                
   Not stratified                               91 (46)
   Stratified                                   108 (54)
  Baseline comparison between study groups:     
   No comparison                                8 (4)
   Comparison but no statistical testing        99 (50)
   Comparison and statistical testing           92 (46)
  Baseline difference between study groups\*:   
   No difference                                55 (60)
   Difference                                   35 (38)
   Unclear about difference                     2 (2)
  Sample size:                                  199
   Median (range) sample size                   286 (14-243 000)
  No of sites:                                  124
  Median (range) No of sites†                   20 (2-862)

\*Denominator is 92 studies with statistical testing of baseline differences.

†Information on number of sites was not provided in 13 multisite trials.

Adjustment practices
--------------------

Among the 199 trials, the most common approach specified in the Methods section was to use an unadjusted analysis either alone (48%) or in conjunction with adjusted analysis (21%), whereas 30% of the trials planned adjusted analysis only. A similar picture was seen in the Results section. There were six trials where the plan in the Methods section was incongruent with what was shown in the Results section: three trials where adjusted analysis were promised in the Methods section but not shown in the Results section and three trials where adjusted analyses appeared in the Results section without being stated in the Methods section. The use or not of adjustment was unclear in both the Methods and the Results sections for two trials (table 2[](#tbl2){ref-type="table"}).

###### 

 Adjustment practices of trials in analysis. Values are numbers (percentages) unless stated otherwise

  Variables                                           Trials (n=199)
  --------------------------------------------------- ----------------
  **Analysis plan in Methods section**                
  Unadjusted only                                     96 (48)
  Adjusted only                                       59 (30)
  Both unadjusted and adjusted                        42 (21)
  Unclear regarding adjustment                        2 (1)
  **Analysis reported in Results section**            
  Unadjusted only                                     96 (48)
  Adjusted only                                       57 (29)
  Both unadjusted and adjusted                        42 (21)
  Unclear regarding adjustment                        4 (2)
  **Adjustment for baseline factors**                 
  Groups were similar:                                
   Not adjusted                                       74 (59)
   Adjusted                                           46 (37)
   Unclear                                            5 (4)
  Groups were different:                              
   Not adjusted                                       18 (41)
   Adjusted                                           25 (57)
   Unclear                                            1 (2)
  Group difference was unclear:                       
   Not adjusted                                       17 (57)
   Adjusted                                           13 (43)
  Adjustment for stratification variables (n=108)\*   
   Not adjusted                                       60 (56)
   Adjusted                                           42 (39)
   Unclear                                            6 (6)
  Any adjustment (stratification or baseline)         
   None                                               95 (48)
   Adjusted                                           99 (50)
   Unclear                                            5 (3)
  No of adjustment variables                          99
  Median (range) No of adjustment variables           3 (1-13)

\*See supplementary file.

Adjustment types
----------------

Ninety nine trials reported adjusted analysis in the Results section (adjusted only n=57, in conjunction with unadjusted n=42). In 92% (91/99) of the trials that used adjustments, the authors presented clearly the exact adjusting variables, whereas in 8% (8/99) of the trials the list of adjusting variables remained unclear. The median number of variables used in the adjustment was 3 (range 1-13, n=91). Ninety two per cent (84/91) adjusted for baseline variables and 46% (42/91) adjusted for stratification variables. The most common variables used for adjustment were age (31%), study center/site (27%), sex (23%), socioeconomic status (9%), smoking (6%), race (5%), body mass index or body weight (5%), and self rated health (5%). Adjustment for baseline variables was substantially more common when significant baseline differences had been found (60% *v* 38%, P=0.02).

Comparison of nominal significance between unadjusted and adjusted analyses
---------------------------------------------------------------------------

Of the 42 trials that performed both unadjusted and adjusted analyses for the selected primary outcomes, the determination of nominal statistical significance was possible for 38 (range 12-49) trials. Twenty eight of them provided specific effect estimates for both types of analyses (table 3[](#tbl3){ref-type="table"}); 10 trials provided nominal significance for both types of analyses but were missing one or both effect estimates (table 4[](#tbl4){ref-type="table"}). Two trials[@ref19] [@ref36] had two comparisons each (two different active interventions versus control), making a total of 40 comparisons: 43% (17/40) had a statistically significant effect with both analyses, 40% (16/40) had non-significant effects with both analyses, and 18% (7/40) had significant effect with only one of the two analyses (three unadjusted only, four adjusted only) (table 3).

###### 

Adjusted and unadjusted estimates of intervention effect (n=28)

  Intervention comparison                                                                                                 Primary outcome                                 Metric                                Unadjusted estimate (95% CI)   Adjusted estimate (95% CI)
  ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------------- ------------------------------ ----------------------------
  Liquid based cytology versus conventional PAP test in screened women^12^                                                Detection of CIN grade II+\*                    Detection rate ratio/incidence rate   0.99 (0.85 to 1.16)            1.00 (0.83 to 1.19)
  Thalidomide versus placebo in lung cancer^13^                                                                           Death                                           Hazard ratio                          1.09 (0.93 to 1.27)            1.11 (0.94 to 1.32)
  Valproic acid versus placebo in amytrophic lateral sclerosis^14^                                                        Death                                           Hazard ratio                          1.67 (0.83 to 3.33)            1.54 (0.75 to 3.22)
  Pralidoxine chloride versus saline placebo in organophosphorus poisoning^15^                                            Death                                           Hazard ratio                          1.82 (1.01 to 3.28)†‡          1.69 (0.88 to 3.26)
  Artemether-lumefantrine versus oral quinine in malaria^16^                                                              Treatment failure                               Hazard ratio                          0.09 (0.03 to 0.30)†           0.09 (0.03 to 0.30)†
  Standard surgery+pelvic lymphadenectomy versus standard surgery in endometrial cancer^17^                               Death                                           Hazard ratio                          1.16 (0.87 to 1.54)            1.04 (0.74 to 1.45)
  Riluzole versus placebo in Parkinson's disease^18^                                                                      Death                                           Hazard ratio                          1.09 (0.88 to 1.35)            1.09 (0.88 to 1.35)
  Selective digestive tract decontamination versus standard care in intensive care unit patients^19^                      Death                                           Hazard ratio                          0.94 (0.82 to 1.08)            0.83 (0.72 to 0.97)†‡
  Selective oropharyngeal tract decontamination versus standard care in intensive care unit patients^19^                  Death                                           Hazard ratio                          0.95 (0.82 to 1.10)            0.86 (0.74 to 0.99)†‡
  Usual care+aerobic exercise training versus usual care alone in heart failure^20^                                       All cause mortality or admission to hospital    Hazard ratio                          0.93 (0.84 to 1.02)            0.89 (0.81 to 0.99)†‡
  Valsartan versus placebo in atrial fibrillation^21^                                                                     Recurrence of atrial fibrillation               Hazard ratio                          0.98 (0.85 to 1.13)            0.97 (0.83 to 1.14)
  Abacavir-lamivudine versus tenofovir-emtricitabine in patients infected with HIV^22^                                    Virologic failure                               Hazard ratio                          2.33 (1.46 to 3.72)†           2.08 (1.28 to 3.37)†
  Laparoscopic versus open resection in colon cancer^23^                                                                  Disease progression                             Hazard ratio                          1.09 (0.87 to 1.35)            1.08 (0.87 to 1.35)
  Capecitabine+trastuzumab versus capecitabine alone in breast cancer^24^                                                 Progression                                     Hazard ratio                          0.69 (0.48 to 0.97)†           0.66 (0.43 to 0.99)†
  Radiotherapy+radical prostatectomy versus radical prostatectomy alone in prostate cancer^25^                            Death or biochemical progression                Hazard ratio /risk ratio              0.53 (0.37 to 0.79)†           0.56 (0.37 to 0.83)†
  Home management versus usual care in patients with malaria^26^                                                          Treatment incidence density per person-year\*   Incidence rate ratio                  0.57 (0.47 to 0.68)†           0.58 (0.49 to 0.70)†
  Antioxidant supplement versus placebo in chronic pancreatitis^27^                                                       Reduction in painful days per month\*           Mean difference                       −4.15 (−6.23 to-2.07)†         −2.33 (−3.51 to −1.15)†
  Local versus systemic steroids in rotator cuff disease^28^                                                              Pain and disability index score                 Mean difference                       −5.2 (−13.9 to 3.5)            −4.1 (−12.3 to 4.1)
  Behavioral analysis+standard treatment versus standard treatment in adults with intellectual disabilities^29^           Aberrant behavior checklist                     Mean difference                       −1.38 (−2.54 to −0.22)†        −0.89 (−1.74 to −0.04)†
  Intracoronary streptokinase versus no additional therapy in patients requiring percutaneous coronary intervention^30^   Infarct size at six months                      Mean difference                       --10.5 (--16.9 to --4.1)†      --10.2 (ND)
  Lifestyle intervention versus control in obese people^31^                                                               Body mass index at 12 months                    Mean difference                       --0.11 (--0.77 to 0.55)        --0.11 (--0.45 to 0.22)
  Terlipressin infusion+banding ligation versus terlipressin infusion alone in acute oesophageal variceal bleeding^32^    Treatment failure, early bleeding               Odds ratio                            0.10 (0.013 to 0.87)†          0.08 (0.010 to 0.63)†
  Routine care+thigh length graduated compression stockings versus routine care in stroke^33^                             Deep vein thrombosis                            Odds ratio                            0.97 (0.75 to 1.26)            0.98 (0.76 to 1.27)
  Peer support versus standard care in women at risk for postpartum depression^34^                                        Depression scale (Edinburgh)                    Odds ratio                            0.47 (0.30 to 0.72)†           0.44 (0.28 to 0.68)†
  Triple therapy versus nicotine patch alone in smokers^35^                                                               Abstinence at 26 weeks\*                        Odds ratio                            0.43 (0.19 to 0.97)†           0.40 (0.16 to 0.95)†
  Hand hygiene only versus control in households^36^                                                                      Secondary attack ratio                          Odds ratio                            0.52 (0.27 to 1.00)            0.57 (0.26 to 1.22)
  Hand hygiene+facemask versus control in households^36^                                                                  Secondary attack ratio                          Odds ratio                            0.67 (0.36 to 1.25)            0.77 (0.38 to 1.55)
  Computer based multirisk assessment report versus standard care in women^37^                                            Interpersonal violence detection\*              Risk ratio                            0.48 (0.22 to 1.00)†‡          0.50 (0.24 to 1.11)
  Computer based medication reconciliation versus standard care in hospital patients^38^                                  Potential adverse drug events                   Risk ratio                            0.74 (0.60 to 0.89)†           0.72 (0.52 to 0.99)†
  Methylprednisolone versus placebo in multiple sclerosis^39^                                                             Relapse rate                                    Risk ratio                            0.37 (0.23 to 0.59)†           0.33 (0.19 to 0.56)†

CIN=cervical intraepithelial neoplasia; NA=no data.

Two trials^19\ 36^ had two comparison categories in each (for example, treatment A versus control and treatment B versus control), making a total of 30 comparisons in 28 trials. Across all trials, effect sizes are presented such that relative risk metrics \<1.00 and mean difference metrics \<0 mean that experimental intervention is better than control intervention.

\*Favorable outcome. Estimates and 95% confidence intervals recalculated for consistency across table: effect size was inverted (1/effect size) for relative risk metrics and was changed sign for mean difference metrics.

†Significant effect based on 95% confidence interval.

‡Discordant results between unadjusted and adjusted effect.

###### 

 Reasons intervention estimates were missing for either unadjusted or adjusted model (n=10)

  Study                  Quotes
  ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adler et al^40^        Adjustment for age and sex had no effect on the results either
  Dumville et al^41^     Time to ulcer healing did not differ between the groups (log rank test 1.00, df=2, P=0.62)
  Lainchbury et al^42^   Cox regression (allowing for time to event, age ≤75 or \>75 years, and time by age interactions), an overall treatment effect spanned the 3 years (P=0.033)
  Muss et al^43^         The rates of relapse in the Capecitabine group were nearly twice those in the standard chemotherapy group (unadjusted). Adjusted estimate was given HR=2.09 . . .
  Piper et al^44^        The same effects (group) were obtained when logistic regression analyses controlled for race, sex, and site
  Plint et al^45^        The relative risk of admission by day 7 in group 1 as compared with group 4 was 0.65 (95% confidence interval, 0.45 to 0.95; P=0.02 and P=0.07 for the unadjusted and adjusted analyses, respectively)
  Hofmeijer et al^46^    These results were the same after adjustment for age . . .
  Spencer et al^47^      PFS adjusted for either . . . or . . . , or both, remained significant
  Kesecioglu et al^48^   The estimated odds ratio for death at day 28 in the usual care group versus the HL 10 group was 0.75 (95% CI, 0.48--1.8; P=0.22). A Kaplan-Meier survival plot for the 28-day mortality is shown in Figure 2 (P=0.34 by log-rank test)
  Vandemheen et al^49^   Adjustment of the results for sex had no effect on the results

Among the seven comparisons (six trials)[@ref15] [@ref19] [@ref20] [@ref37] [@ref42] [@ref45] with discrepant levels of nominal significance in unadjusted versus adjusted analyses, the authors interpreted the trial focusing primarily on the statistically significant result in four trials (five comparisons)[@ref19] [@ref37] [@ref42] [@ref45] where the experimental treatment tended to be better. Conversely, they focused primarily on the non-statistically significant result in one trial[@ref15] where the experimental treatment was worse. Finally, the authors of one trial carefully balanced between the significant and non-significant results, admitting that according to the primary analysis plan the results were non-significant.[@ref20]

Discussion
==========

This empirical evaluation shows that there is wide diversity in adjustment practices for the analysis of primary outcomes in randomized controlled trials. The use or not of adjustments can make a substantial difference in the statistical inferences for several trials. In 18% of the comparisons that provided both adjusted and unadjusted analysis results, nominal statistical significance was attained with only one of the two approaches; in six of these seven cases, authors focused primarily on the result that was more favorable or less unfavorable for the experimental treatment. The lack of standardization in adjustment practices offers an opportunity for subjectively steering the results of randomized controlled trials towards specific conclusions. Registries generally did not include information on this aspect of the analysis, few trials had published design papers, and protocols could be obtained from authors for the minority of the trials. Even then, analysis plans regarding model adjustment disagreed between the available information in the protocol and the published trial in about half of the cases.

Selective reporting
-------------------

In the current practice, it is not possible to evaluate whether the analysis plan changed between the original protocol and main trial paper using the trial registries. Although most trials that we evaluated were registered, the information regarding statistical analyses, specifically model adjustment, was rarely provided. Only 12% of registry records provided study results and in only half of those cases was information on adjustment given. Trial investigators should provide full protocols with detailed analysis plans to the registry prior to conducting the study. Analysis plans in the registry, protocol, or design paper disagreed with the plans in the published paper in approximately half of the studies. It is unlikely that the disagreement rate would be lower in the trials where the protocol was neither publicly available nor retrievable from the authors. Our findings are consistent with a growing literature on selective reporting of outcomes and analyses in diverse study designs, including randomized controlled trials. Other empirical studies[@ref50] [@ref51] [@ref52] have shown selective reporting based on comparisons of protocols and published results; many outcomes specified in the protocols were missing in the published reports, while new outcomes were introduced.

We observed large variability in terms of the practices of adjustment for stratification or baseline variables. Less than half of the trials that used a stratified randomization technique adjusted the model for the stratification variables, even though this is suggested by both the CONSORT and the ICH E9 guidelines. Although we do not advocate testing for differences in baseline variables, our results showed that more trials adjusted for baseline variables when significant differences had been noted between the compared arms in these variables; however, there were many exceptions to this pattern. Many studies with significant differences at baseline did not adjust for them and many studies without significant differences still adjusted for baseline factors. This inconsistency is not surprising since a consensus does not exist on testing and adjusting for multicenter trials. The studies that adjusted for center typically did not report the exact model that they used to adjust for site. Multiple approaches exist to account for site in the analysis, and results may differ among them.[@ref1] Another empirical study found that only 25% among a sample of trials published in 2000 and 2006 reported adjusted analyses and only 5% and 10% of trials in these two years reported both adjusted and unadjusted analyses. The respective proportions were higher in our survey, but they were still low, and the difference may reflect the more select nature of our sample of trials (trials published in major journals) rather than improvement in reporting of adjustments over time.[@ref53]

The adjusted model occasionally lacked information regarding which covariates it included. Sometimes the text specified the list of covariates that were tested in univariate analyses against the outcome, but did not report which of them qualified for the final adjusted model[@ref54]; whereas in other trials the text reported covariates that were significantly associated with the outcome without mentioning whether the adjusted model also contained any non-significant covariates.[@ref55] [@ref56] Flexibility in the use of different combinations of covariates provides an additional mechanism for "vibration of effects." Different adjustment choices may yield different results and opens a window for potential selective reporting.

Limitations of this study
-------------------------

Our analysis has limitations. Inaccurate reporting of the methods and results cannot be excluded. However, the Methods and Results sections were almost always congruent in specifying the types of analyses. Moreover, some data were missing in the published reports. The estimates for the intervention effect and the associated significance levels were not mentioned in several trials that performed both unadjusted and adjusted analysis. Thus one would be unable to see the magnitude of the differences, if any, between the two analytical approaches. Finally, despite our intense efforts we could not retrieve the protocols for more than two thirds of the trials. It does not necessarily follow that these trials suffer from selective reporting, but lack of transparency creates opportunities for such bias.

Conclusions
-----------

We have shown the potential of selective reporting on the primary outcomes of trials published in the most high profile clinical journals, due to the alternative choices on how to adjust or not the results of these outcomes. Adjustments may affect the interpretation of the study findings and eventually their impact on medical practice and policy. Other authors have also identified that non-significant results in randomized controlled trials are subject to "spin" in their interpretation to make them seem more favorable.[@ref57] Overall, the plethora of analytical and interpretation options may infuse subjectivity in the evidence procured by randomized controlled trials. One possibility to help minimize these problems is to request that registered protocols should present in meticulous detail any adjustments plans for the main outcomes. Significant advances have been made in trial registration[@ref58] [@ref59] and there is impetus to improve also the quality of registered protocols. For example, the SPIRIT initiative recommends that protocols explicitly specify whether an adjusted analysis will be undertaken; and if so, to list the adjustment variables as well as techniques to handle them in the model.[@ref60] This is in line with efforts in other biomedical fields, where the movement of reproducible research has led to the request to deposit detailed protocols, analytical codes, and the raw data of published studies.[@ref61] [@ref62] [@ref63] [@ref64] [@ref65] Increased transparency regarding the choices of adjusted and unadjusted analyses may enhance the reliability of inferences from randomized trials.

### What is already known on this topic

1.  At present the imbalance between study groups in randomized controlled trials is inconsistently handled

2.  Some studies adjust the outcome model for baseline differences among study groups, whereas others consider them chance findings or not even worth consideration

3.  Different choices for adjustment may lead to different estimates of the treatment effect and levels of statistical significance

### What this study adds

1.  Covariates are handled in diverse ways in the analysis of primary outcomes of randomized controlled trials

2.  It is common for analysis plans on adjustments to differ between protocols and published papers, but this can be discerned only when protocols are obtained from authors, since detailed information on the analysis plan is rarely available

3.  Moreover, unadjusted versus adjusted results sometimes differ in the level of nominal significance, and investigators usually select to report the more favorable results
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